Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect Agios Pharmaceuticals to post earnings of ($1.57) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.20. The company had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The firm’s revenue for the quarter was up 46.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.47) earnings per share. On average, analysts expect Agios Pharmaceuticals to post $-2 EPS for the current fiscal year and $-6 EPS for the next fiscal year.
Agios Pharmaceuticals Price Performance
AGIO stock traded up $0.34 during midday trading on Tuesday, hitting $47.77. The stock had a trading volume of 35,472 shares, compared to its average volume of 788,005. The business has a 50-day moving average of $43.48 and a two-hundred day moving average of $34.00. Agios Pharmaceuticals has a 52-week low of $19.80 and a 52-week high of $50.35.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on AGIO
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Further Reading
- Five stocks we like better than Agios Pharmaceuticals
- What to Know About Investing in Penny Stocks
- This Semiconductor Stock Is ON Track for a New High
- Health Care Stocks Explained: Why You Might Want to Invest
- Why SoFi Stock is an Unmissable Growth Opportunity
- Options Trading – Understanding Strike Price
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.